Ascorbyl free radical reflects catalytically active iron after intravenous iron saccharate injection

Free Radical Biology and Medicine

Volumn 45, Issue 9, 2008, Pages 1302-1307

  Stefánsson, Bergur V ^a   Haraldsson, Börje ^a   Nilsson, Ulf ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Ascorbyl free radical; Electron spin resonance; Free radicals; Hemodialysis; Iron saccharate; Non transferrin bound iron; Oxidative stress

Indexed keywords

ASCORBIC ACID; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; ERYTHROPOIETIN; FREE RADICAL; IRON; IRON SACCHARATE; MYELOPEROXIDASE; NICOTINAMIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TRANSFERRIN;

ADULT; ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTRON SPIN RESONANCE; FEMALE; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; CATALYSIS; ELECTRON SPIN RESONANCE SPECTROSCOPY; FEMALE; FERRIC COMPOUNDS; FREE RADICALS; HEMATINICS; HUMANS; IRON; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 53449097764     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.08.006     Document Type: Article

References (38)

1. Macdougall I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int. Suppl. 69 (1999) S61-S66
2. Macdougall I.C., Tucker B., Thompson J., Tomson C.R., Baker L.R., and Raine A.E. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 50 (1996) 1694-1699
3. Kooistra M.P., and Marx J.J. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol. Dial. Transplant. 13 (1998) 2578-2582
4. Parkkinen J., von Bonsdorff L., Peltonen S., Gronhagen-Riska C., and Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol. Dial. Transplant. 15 (2000) 1827-1834
5. Kooistra M.P., Kersting S., Gosriwatana I., Lu S., Nijhoff-Schutte J., Hider R.C., and Marx J.J. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur. J. Clin. Invest. 32 Suppl. 1 (2002) 36-41
6. Van Wyck D., Anderson J., and Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol. Dial. Transplant. 19 (2004) 561-565
7. Foley R.N., and Parfrey P.S. Cardiovascular disease and mortality in ESRD. J. Nephrol. 11 (1998) 239-245
8. Himmelfarb J., and McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif. 19 (2001) 200-205
9. Stenvinkel P. Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif. 19 (2001) 143-151
10. Wratten M.L., Galaris D., Tetta C., and Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid. Redox Signal. 4 (2002) 935-944
11. Maruyama Y., Nakayama M., Yoshimura K., Nakano H., Yamamoto H., Yokoyama K., and Lindholm B. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels. Nephrol. Dial. Transplant. 22 (2007) 1407-1412
12. Lim P.S., Wei Y.H., Yu Y.L., and Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol. Dial. Transplant. 14 (1999) 2680-2687
13. Roob J.M., Khoschsorur G., Tiran A., Horina J.H., Holzer H., and Winklhofer-Roob B.M. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J. Am. Soc. Nephrol. 11 (2000) 539-549
14. Herrera J., Nava M., Romero F., and Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am.J. Kidney Dis. 37 (2001) 750-757
15. Salahudeen A.K., Oliver B., Bower J.D., and Roberts II L.J. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int. 60 (2001) 1525-1531
16. Drueke T., Witko-Sarsat V., Massy Z., Descamps-Latscha B., Guerin A.P., Marchais S.J., Gausson V., and London G.M. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106 (2002) 2212-2217
17. Galleano M., Aimo L., and Puntarulo S. Ascorbyl radical/ascorbate ratio in plasma from iron overloaded rats as oxidative stress indicator. Toxicol. Lett. 133 (2002) 193-201
18. Rooyakkers T.M., Stroes E.S., Kooistra M.P., van Faassen E.E., Hider R.C., Rabelink T.J., and Marx J.J. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur. J. Clin. Invest. 32 Suppl. 1 (2002) 9-16
19. Tovbin D., Mazor D., Vorobiov M., Chaimovitz C., and Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am. J. Kidney Dis. 40 (2002) 1005-1012
20. Day S.M., Duquaine D., Mundada L.V., Menon R.G., Khan B.V., Rajagopalan S., and Fay W.P. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 107 (2003) 2601-2606
21. Michelis R., Gery R., Sela S., Shurtz-Swirski R., Grinberg N., Snitkovski T., Shasha S.M., and Kristal B. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol. Dial. Transplant. 18 (2003) 924-930
22. Anraku M., Kitamura K., Shinohara A., Adachi M., Suenga A., Maruyama T., Miyanaka K., Miyoshi T., Shiraishi N., Nonoguchi H., Otagiri M., and Tomita K. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int. 66 (2004) 841-848
23. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., Schwab S.J., and Goodkin D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339 (1998) 584-590
24. Kletzmayr J., and Horl W.H. Iron overload and cardiovascular complications in dialysis patients. Nephrol. Dial. Transplant. 17 Suppl. 2 (2002) 25-29
25. Schaller G., Scheiber-Mojdehkar B., Wolzt M., Puttinger H., Mittermayer F., Horl W.H., Fodinger M., Sunder-Plassmann G., and Vychytil A. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 68 (2005) 2814-2822
26. Scheiber-Mojdehkar B., Lutzky B., Schaufler R., Sturm B., and Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J. Am. Soc. Nephrol. 15 (2004) 1648-1655
27. Tiranathanagul K., Eiam-Ong S., Tosukhowong P., Praditpornsilpa K., and Tungsanga K. Oxidative stress from rapid versus slow intravenous iron replacement in haemodialysis patients. Nephrology (Carlton) 9 (2004) 217-222
28. Kozlov A.V., Yegorov D., Vladimirov Y.A., and Azizova O.A. Intracellular free iron in liver tissue and liver homogenate: studies with electron paramagnetic resonance on the formation of paramagnetic complexes with desferal and nitric oxide. Free Radic. Biol. Med. 13 (1992) 9-16
29. Ahotupa M., Ruutu M., and Mantyla E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin. Biochem. 29 (1996) 139-144
30. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin. Biochem. 37 (2004) 277-285
31. Rice-Evans C., and Miller N.J. Total antioxidant status in plasma and body fluids. Methods Enzymol. 234 (1994) 279-293
32. Reznick A.Z., and Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 233 (1994) 357-363
33. Breuer W., Ermers M.J., Pootrakul P., Abramov A., Hershko C., and Cabantchik Z.I. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97 (2001) 792-798
34. Zanen A.L., Adriaansen H.J., van Bommel E.F., Posthuma R., and Th. de Jong G.M. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol. Dial. Transplant. 11 (1996) 820-824
35. Roginsky V.A., and Stegmann H.B. Ascorbyl radical as natural indicator of oxidative stress: quantitative regularities. Free Radic. Biol. Med. 17 (1994) 93-103
36. Sharma M.K., and Buettner G.R. Interaction of vitamin C and vitamin E during free radical stress in plasma: an ESR study. Free Radic. Biol. Med. 14 (1993) 649-653
37. Minetti M., Forte T., Soriani M., Quaresima V., Menditto A., and Ferrari M. Iron-induced ascorbate oxidation in plasma as monitored by ascorbate free radical formation: no spin-trapping evidence for the hydroxyl radical in iron-overloaded plasma. Biochem. J. 282 Pt. 2 (1992) 459-465
38. Bielski B., Allen A., and Schwarz H. Mechanism of disproportionation of ascorbate radicals. J. Am. Chem. Soc. 103 (1981) 3116-3118